Rafael Holdings, Inc. (NYSE:RFL) Sees Large Decrease in Short Interest

Rafael Holdings, Inc. (NYSE:RFL) saw a significant decline in short interest during the month of February. As of February 13th, there was short interest totaling 38,452 shares, a decline of 27.5% from the January 29th total of 53,017 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 70,001 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 70,001 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the company’s shares are short sold.

Rafael Trading Up 15.7%

Rafael stock traded up $0.20 during trading on Monday, hitting $1.47. The company had a trading volume of 457,705 shares, compared to its average volume of 59,484. The company’s 50 day simple moving average is $1.23 and its 200-day simple moving average is $1.32. Rafael has a 1-year low of $1.12 and a 1-year high of $3.19. The stock has a market cap of $76.10 million, a price-to-earnings ratio of -1.73 and a beta of 0.68.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rafael in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RFL. Simplex Trading LLC purchased a new stake in Rafael during the 2nd quarter worth approximately $32,000. Marshall Wace LLP acquired a new position in Rafael during the 2nd quarter worth $50,000. Americana Partners LLC acquired a new stake in Rafael in the 2nd quarter valued at about $76,000. Citadel Advisors LLC boosted its stake in shares of Rafael by 132.3% in the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after buying an additional 41,335 shares during the period. Finally, Cable Car Capital LP acquired a new position in shares of Rafael during the second quarter worth about $173,000. Hedge funds and other institutional investors own 11.30% of the company’s stock.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.